TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12085609

Group type: EXPERIMENTAL
Intervention: Functional neuromuscular stimulation (FNS)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Able-bodied standing
Number of subjects: 7
Study: 10189121

Group type: EXPERIMENTAL
Intervention: 0.5 g/kg glucose
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 1.0 g/kg glucose
Number of subjects: 10
Study: 7750002

Group type: EXPERIMENTAL
Intervention: Changes in house dust mite allergen Der p I exposure
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Changes in house dust mite allergen concentration in the living room floor
Number of subjects: 34
Study: 2405736

Group type: EXPERIMENTAL
Intervention: Metoclopramide 0.15 mg/kg
Number of subjects: 126

Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 126
Study: 6311913

Group type: EXPERIMENTAL
Intervention: DPT + PRP vaccine
Number of subjects: 78

Group type: COMPARATOR
Intervention: DPT vaccine
Number of subjects: 78
Study: 30523712

Group type: EXPERIMENTAL
Intervention: Venetoclax-rituximab
Number of subjects: 194

Group type: COMPARATOR
Intervention: Bendamustine-rituximab
Number of subjects: 194
Study: 29726319

Group type: EXPERIMENTAL
Intervention: Home-based chemotherapy (group A: four treatments at home followed by three in an outpatient clinic)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Outpatient chemotherapy (group B: three treatments in an outpatient clinic followed by four at home)
Number of subjects: 51
Study: 26730818

Group type: EXPERIMENTAL
Intervention: TPV/r 500/100 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TPV/r 500/200 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: LPV/r 400/100 mg
Number of subjects: 0
Study: 25022299

Group type: EXPERIMENTAL
Intervention: Microbial sealant (InteguSeal)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Plain adhesive drape (control group)
Number of subjects: 96
Study: 22822007

Group type: EXPERIMENTAL
Intervention: DNA risk assessment communication
Number of subjects: 497

Group type: COMPARATOR
Intervention: Standard risk assessment communication
Number of subjects: 497
Study: 20652333

Group type: EXPERIMENTAL
Intervention: Landiolol at 30 μg/kg/min
Number of subjects: 30

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 30
Study: 17211705

Group type: EXPERIMENTAL
Intervention: 10 mg omeprazole once daily
Number of subjects: 8

Group type: COMPARATOR
Intervention: 20 mg famotidine twice daily
Number of subjects: 8
Study: 17025373

Group type: EXPERIMENTAL
Intervention: High-dose vitamin E supplementation
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 12719045

Group type: EXPERIMENTAL
Intervention: rocuronium (0.9 mg kg(‐1))
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: mivacurium (0.25 mg kg(‐1))
Number of subjects: 20
Study: 11303324

Group type: EXPERIMENTAL
Intervention: Elevated homocysteine levels in CAD patients (mean 13.61 +/- 4.5 mumol/L)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Elevated homocysteine level defined as > or = 12.83 mumol/L
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 5 mumol/L increment in homocysteine level
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Elevated homocysteine level
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Homocysteine levels in patients with elevated levels
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Correlation between homocysteine and folate levels
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Correlation between homocysteine and vitamin B12 concentrations
Number of subjects: 100
Study: 9019574

Group type: EXPERIMENTAL
Intervention: Spersallerg eye drops
Number of subjects: 47
Study: 1290619

Group type: EXPERIMENTAL
Intervention: Losartan (DuP 753, MK‐954) at doses of 5, 10, 20, 40, 80, and 120 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Losartan (DuP 753, MK‐954)
Number of subjects: 0
Study: 6365501

Group type: EXPERIMENTAL
Intervention: Blood-glucose self-testing (5 tests daily)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Self-testing of urinary glucose (4 tests)
Number of subjects: 27
Study: 29625857

Group type: EXPERIMENTAL
Intervention: COPE programme
Number of subjects: 66

Group type: COMPARATOR
Intervention: Usual institutional management (Control)
Number of subjects: 66
Study: 28749745

Group type: EXPERIMENTAL
Intervention: Pro-alcohol episode with no epilogue
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pro-alcohol episode with epilogue
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anti-alcohol episode with epilogue
Number of subjects: 0
Study: 26775514

Group type: EXPERIMENTAL
Intervention: Exercise rehabilitation (Δ50%W intensity, 30 min/day, 5 days/week for 12 weeks)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 10
Study: 23958540

Group type: EXPERIMENTAL
Intervention: Linaclotide 290 μg once daily for 26 weeks
Number of subjects: 805

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 805
Study: 21081243

Group type: EXPERIMENTAL
Intervention: Metreleptin (0.04 mg/kg subcutaneously once daily; n = 5)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo (n = 4)
Number of subjects: 9
Study: 18182396

Group type: EXPERIMENTAL
Intervention: hMG stimulation
Number of subjects: 104

Group type: COMPARATOR
Intervention: FSH stimulation
Number of subjects: 104
Study: 16084677

Group type: EXPERIMENTAL
Intervention: Intermittent catheterization (IMC group)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Indwelling catheterization (IDC group)
Number of subjects: 81
Study: 12509304

Group type: EXPERIMENTAL
Intervention: NEO‐FFI (Neuroticism, Extraversion and Other ‐ Five‐Factor Inventory)
Number of subjects: 0
Study: 10834715

Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg/day of rHGH
Number of subjects: 28

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 28
Study: 8864715

Group type: EXPERIMENTAL
Intervention: Pentoxifylline 400 mg t.i.d. for 9 months
Number of subjects: 289

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 289
Study: 1741200

Group type: EXPERIMENTAL
Intervention: Continuous amoxicillin (twice a day every day for up to 4 months)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Intermittent amoxicillin (twice a day only when respiratory symptoms developed for up to 4 months)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Continuous amoxicillin
Number of subjects: 55

Group type: COMPARATOR
Intervention: Intermittent amoxicillin
Number of subjects: 55
Study: 6535988

Group type: COMPARATOR
Intervention: Radiotherapy
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Combined method (brachytherapy and surgery)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Teletherapy with radical operation
Number of subjects: 60
Study: 31972848

Group type: EXPERIMENTAL
Intervention: Health literacy-focused Type 2 diabetes self-management intervention
Number of subjects: 250

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 250
Study: 30878711

Group type: EXPERIMENTAL
Intervention: Penicillin Skin Test Kit (containing penicilloyl polylysine, minor determinant mixture, and amoxicillin)
Number of subjects: 455

Group type: EXPERIMENTAL
Intervention: Amoxicillin challenge (250 mg)
Number of subjects: 455
Study: 27905821

Group type: EXPERIMENTAL
Intervention: 3 doses of booster hepatitis B vaccination (0-1-6 month, 20 µg)
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Group III (1.0 to <10.0 mIU/mL)
Number of subjects: 225
Study: 25876795

Group type: EXPERIMENTAL
Intervention: Cognitive Methods adherence (within-patient)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Cognitive Methods adherence (between-patient)
Number of subjects: 57
Study: 24310853

Group type: EXPERIMENTAL
Intervention: LA-IP approach
Number of subjects: 4

Group type: COMPARATOR
Intervention: LA-OP approach
Number of subjects: 4
Study: 23046320

Group type: EXPERIMENTAL
Intervention: Drug-eluting balloon (DEB)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional angioplasty balloon (AB)
Number of subjects: 50
Study: 19573752

Group type: EXPERIMENTAL
Intervention: Woven polyester grafts
Number of subjects: 303

Group type: COMPARATOR
Intervention: Expanded polytetrafluoroethylene (ePTFE) grafts
Number of subjects: 303
Study: 17296571

Group type: EXPERIMENTAL
Intervention: Low frequency ERT (once every 4 weeks)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Standard frequency ERT (once every week or fortnight)
Number of subjects: 11
Study: 15572495

Group type: EXPERIMENTAL
Intervention: Mifepristone (10 mg)
Number of subjects: 2065

Group type: COMPARATOR
Intervention: Levonorgestrel (2 doses of 750 microg given 12 hours apart)
Number of subjects: 2065

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 2065
Study: 11242382

Group type: EXPERIMENTAL
Intervention: Cotrel‐Dubousset instrumentation
Number of subjects: 70

Group type: COMPARATOR
Intervention: No instrumentation
Number of subjects: 70
Study: 9272334

Group type: EXPERIMENTAL
Intervention: DTPwc
Number of subjects: 0

Group type: COMPARATOR
Intervention: DTaP vaccines
Number of subjects: 0

Group type: COMPARATOR
Intervention: DT vaccines
Number of subjects: 0
Study: 8354869

Group type: EXPERIMENTAL
Intervention: Automated disinfection with 2% glutaraldehyde and 70% alcohol rinse
Number of subjects: 60

Group type: COMPARATOR
Intervention: Manual disinfection with 2% glutaraldehyde and 70% alcohol rinse
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both automated and manual disinfection
Number of subjects: 60

Group type: COMPARATOR
Intervention: Manual disinfection
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Automated disinfection
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Endoscopes (general)
Number of subjects: 60
Study: 3725520

Group type: EXPERIMENTAL
Intervention: EMG biofeedback training
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 22
Study: 31763316

Group type: EXPERIMENTAL
Intervention: Functional endoscopic sinus surgery (Group A)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard medical treatment (Group B)
Number of subjects: 0
Study: 29348382

Group type: EXPERIMENTAL
Intervention: Ophiocephalus striatus extract (10 g per day for 14 days)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study: 26643931

Group type: EXPERIMENTAL
Intervention: TIVc
Number of subjects: 2055

Group type: COMPARATOR
Intervention: TIVf
Number of subjects: 2055
Study: 24512337

Group type: EXPERIMENTAL
Intervention: 3-hour intimate touch instructional laboratory with subsequent clinical experience
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clinical experience only (control group)
Number of subjects: 0
Study: 22504513

Group type: EXPERIMENTAL
Intervention: Primary stent implantation
Number of subjects: 50

Group type: COMPARATOR
Intervention: Percutaneous transluminal angioplasty (PTA)
Number of subjects: 50
Study: 19574917

Group type: EXPERIMENTAL
Intervention: Lissamine green (LG)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Rose bengal (RB)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both LG and RB
Number of subjects: 30
Study: 17697449

Group type: EXPERIMENTAL
Intervention: Etoricoxib (90 mg daily)
Number of subjects: 816

Group type: EXPERIMENTAL
Intervention: Etoricoxib (120 mg daily)
Number of subjects: 816

Group type: EXPERIMENTAL
Intervention: Placebo to etoricoxib (90 mg)
Number of subjects: 816

Group type: COMPARATOR
Intervention: Naproxen (500 mg twice daily)
Number of subjects: 816
Study: 15138671

Group type: EXPERIMENTAL
Intervention: Dopexamine (DX, n=10)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Dobutamine (DO, n=10)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Dopamine (DA, n=10)
Number of subjects: 30
Study: 12009282

Group type: EXPERIMENTAL
Intervention: SPf66/QS-21 vaccine
Number of subjects: 89

Group type: COMPARATOR
Intervention: SPf66/alum vaccine
Number of subjects: 89
Study: 10233114

Group type: EXPERIMENTAL
Intervention: Explosive-strength training (32% of training volume)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (3% of training volume explosive-type strength training)
Number of subjects: 18
Study: 7744475

Group type: EXPERIMENTAL
Intervention: Standard reaming technique
Number of subjects: 19

Group type: COMPARATOR
Intervention: Modified reaming technique
Number of subjects: 19
Study: 2169783

Group type: EXPERIMENTAL
Intervention: Granisetron (40 micrograms/kg, single prophylactic dose)
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Granisetron (40 micrograms/kg, additional doses)
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Granisetron (40 micrograms/kg)
Number of subjects: 227

Group type: COMPARATOR
Intervention: Chlorpromazine plus dexamethasone (conventional anti-emetic regimen)
Number of subjects: 227
Study: 7301160

Group type: EXPERIMENTAL
Intervention: Preoperative skin disinfection with povidone-iodine 10% (Betadine) and application of 10% povidone-iodine solution before skin closure.
Number of subjects: 220

Group type: COMPARATOR
Intervention: Preoperative skin disinfection with alcohol 70% and iodine-tincture 2%, and disinfection with iodine before skin suturing.
Number of subjects: 220
Study: 31569652

Group type: EXPERIMENTAL
Intervention: Frozen waterway trail open (10 km, 8-10 weeks)
Number of subjects: 466

Group type: COMPARATOR
Intervention: Land-based trails accessible before and after the intervention
Number of subjects: 466
Study: 28274889

Group type: EXPERIMENTAL
Intervention: Vitamin D3 50,000 IU monthly for 24 months
Number of subjects: 413

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 413
Study: 26466468

Group type: EXPERIMENTAL
Intervention: Volar locking compression plate
Number of subjects: 122

Group type: COMPARATOR
Intervention: External fixation
Number of subjects: 122
Study: 23999674

Group type: EXPERIMENTAL
Intervention: Low AA group: 1 g/kg/d of parenteral amino acids, increasing by 1 g/kg daily until a maximum of 4 g/kg/d
Number of subjects: 150

Group type: COMPARATOR
Intervention: High AA group: 3 g/kg/d of parenteral amino acids, increasing by 1 g/kg daily until a maximum of 4 g/kg/d
Number of subjects: 150
Study: 21403636

Group type: EXPERIMENTAL
Intervention: 0.5 mg sublingual testosterone (with hydroxypropyl‐β‐cyclodextrin carrier)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study: 19016815

Group type: EXPERIMENTAL
Intervention: Oral antibiotics (ciprofloxacin and metronidazole)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Intravenous antibiotics (ciprofloxacin and metronidazole)
Number of subjects: 79
Study: 17942000

Group type: EXPERIMENTAL
Intervention: e-mail with attachment I (short one)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: e-mail with attachment II (long one)
Number of subjects: 119

Group type: COMPARATOR
Intervention: no information (control)
Number of subjects: 119
Study: 12795852

Group type: EXPERIMENTAL
Intervention: Paclitaxel liposome at 135 mg/m² each session, combined with ADM or DDP for two cycles (3 weeks per cycle)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Traditional taxol at 135 mg/m² each session, combined with ADM or DDP for two cycles (3 weeks per cycle)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Paclitaxel liposome
Number of subjects: 129

Group type: COMPARATOR
Intervention: Traditional taxol
Number of subjects: 129
Study: 11017151

Group type: EXPERIMENTAL
Intervention: Altered peptide ligand of myelin basic protein (5 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8634809

Group type: EXPERIMENTAL
Intervention: 50% glycolic acid applied topically for 5 minutes once weekly for 4 weeks
Number of subjects: 41

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 41
Study: 1486710

Group type: EXPERIMENTAL
Intervention: DL-cysteine
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: DL-methionine-methyl sulphonium chloride
Number of subjects: 137

Group type: COMPARATOR
Intervention: Graduated compression bandaging
Number of subjects: 137
Study: 6511520

Group type: EXPERIMENTAL
Intervention: Hyperthermia with radiation
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Hyperthermia alone
Number of subjects: 161
Study: 2873863

Group type: EXPERIMENTAL
Intervention: Intravenous somatostatin (100 micrograms/h)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Physiological saline (control)
Number of subjects: 6
Study: 31962348

Group type: EXPERIMENTAL
Intervention: Evidence-based rehabilitation treatments
Number of subjects: 0

Group type: COMPARATOR
Intervention: Alternative research designs (e.g. case-control studies, cohort studies, observational studies)
Number of subjects: 0
Study: 29761273

Group type: EXPERIMENTAL
Intervention: 2D observation of a consultant surgeon performing a training task on the daVinci S robotic system
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 3D observation of a consultant surgeon performing a training task on the daVinci S robotic system
Number of subjects: 90

Group type: COMPARATOR
Intervention: No observation control
Number of subjects: 90
Study: 25964375

Group type: EXPERIMENTAL
Intervention: Presentation within 3 hours of last known well
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Longer onset to door (OTD) intervals
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Time >3 hours
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Earlier presentation
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Time to presentation
Number of subjects: 137
Study: 24708232

Group type: EXPERIMENTAL
Intervention: Telephone-based counseling using principles of motivational interviewing and telehealth home monitoring
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 19
Study: 23253084

Group type: EXPERIMENTAL
Intervention: Neuromuscular blockade (NMB)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (without NMB)
Number of subjects: 40
Study: 20124885

Group type: EXPERIMENTAL
Intervention: Metoprolol 5 mg intravenously three times at 2‐min intervals
Number of subjects: 164

Group type: COMPARATOR
Intervention: Morphine 5 mg intravenously followed by metoprolol 5 mg three times intravenously
Number of subjects: 164
Study: 18216158

Group type: EXPERIMENTAL
Intervention: US and CD guided injection with sclerosing polidocanol
Number of subjects: 32

Group type: COMPARATOR
Intervention: Local anaesthetic lidocaine plus epinephrine
Number of subjects: 32
Study: 16175618

Group type: EXPERIMENTAL
Intervention: Alendronate 70 mg per week for 1 year
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 12960496

Group type: EXPERIMENTAL
Intervention: Glucosamine sulfate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chondroitin sulfate
Number of subjects: 0
Study: 11058482

Group type: EXPERIMENTAL
Intervention: Nicotine transdermal patch (21 mg/day) with atypical antipsychotic medications
Number of subjects: 45

Group type: COMPARATOR
Intervention: Nicotine transdermal patch (21 mg/day) with typical antipsychotic medications
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Nicotine transdermal patch (21 mg/day) with either atypical or typical antipsychotic medications
Number of subjects: 45
Study: 8610897

Group type: EXPERIMENTAL
Intervention: Sevoflurane anesthesia
Number of subjects: 14

Group type: COMPARATOR
Intervention: Isoflurane anesthesia
Number of subjects: 14
Study: 1279502

Group type: EXPERIMENTAL
Intervention: Cocaine solution
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Xylometazoline/lidocaine solution
Number of subjects: 0
Study: 6233054

Group type: EXPERIMENTAL
Intervention: Electromagnetic fields of extremely low frequency (EMF of ELF)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no EMF treatment)
Number of subjects: 30
Study: 30700617

Group type: EXPERIMENTAL
Intervention: Subarachnoid block combined with continuous transverse abdominis plane block (group TAP)
Number of subjects: 72

Group type: COMPARATOR
Intervention: General anesthesia alone (group GA)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Subarachnoid block alone (group SAB)
Number of subjects: 72
Study: 29126857

Group type: EXPERIMENTAL
Intervention: Yohimbine (21.6mg)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 27435723

Group type: EXPERIMENTAL
Intervention: Evidence-based quality improvement approach (EBQI) to tailoring Patient Aligned Care Teams (PACT) for women Veterans (WH-PACT)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: WH-PACT care
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: EBQI-supported WH-PACT implementation
Number of subjects: 12
Study: 24969339

Group type: EXPERIMENTAL
Intervention: 2.0-mm clear corneal micro-incision cataract surgery (MICS)
Number of subjects: 34

Group type: COMPARATOR
Intervention: 2.65-mm small-incision cataract surgery (SICS)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Both MICS and SICS groups
Number of subjects: 34
Study: 22877814

Group type: EXPERIMENTAL
Intervention: Lottery-based incentive
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (no lottery intervention)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Lottery-based incentive (among patients with baseline INR below therapeutic range)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (among patients with baseline INR below therapeutic range)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Lottery-based incentive (among patients with low INR at baseline)
Number of subjects: 100
Study: 20872304

Group type: EXPERIMENTAL
Intervention: Simulation‐based error training (SET)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Video‐based guided error training (VGET)
Number of subjects: 32
Study: 18509324

Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Number of subjects: 5035

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5035
Study: 16021649

Group type: EXPERIMENTAL
Intervention: Insulin glargine once daily at bedtime
Number of subjects: 585

Group type: COMPARATOR
Intervention: NPH insulin (once- or twice-daily)
Number of subjects: 585

Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 585

Group type: COMPARATOR
Intervention: NPH insulin
Number of subjects: 585

Group type: EXPERIMENTAL
Intervention: Insulin glargine (for those on >1 basal insulin injection prior to study)
Number of subjects: 585

Group type: COMPARATOR
Intervention: NPH insulin (for those on >1 basal insulin injection prior to study)
Number of subjects: 585
Study: 12540987

Group type: EXPERIMENTAL
Intervention: Nebivolol (2.5 mg and 5 mg, n = 6)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (n = 6)
Number of subjects: 12
Study: 10751261

Group type: EXPERIMENTAL
Intervention: Somatosensory evoked potentials (SEPs) including median, posterior tibial, and peroneal SEPs
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Derived spinal conduction time
Number of subjects: 69

Group type: COMPARATOR
Intervention: Median CCTs
Number of subjects: 69